These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 36947324

  • 1. Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study.
    Oya T, Ichikawa Y, Nakamura S, Tomita Y, Sasaki T, Inoue T, Sakuma H.
    Ann Nucl Med; 2023 Jun; 37(6):360-370. PubMed ID: 36947324
    [Abstract] [Full Text] [Related]

  • 2. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL, Xue YL, Song HJ, Luo QY.
    Nucl Med Commun; 2012 Dec 26; 33(12):1232-42. PubMed ID: 23111353
    [Abstract] [Full Text] [Related]

  • 4. Quantitative 99mTc-MDP SPECT/CT as an alternative to 18F-NaF PET/CT for objective assessment of osteoblastic bone metastases.
    Coskun N, Cagdas B, Yildirim N.
    Hell J Nucl Med; 2022 Dec 26; 25(2):132-137. PubMed ID: 35913859
    [Abstract] [Full Text] [Related]

  • 5. The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer.
    Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, Kupferschlaeger J, la Fougère C.
    J Nucl Med; 2021 Jan 26; 62(1):48-54. PubMed ID: 32444369
    [Abstract] [Full Text] [Related]

  • 6. Quantitative [99mTc]Tc-MDP SPECT/CT correlated with [18F]NaF PET/CT for bone metastases in patients with prostate cancer.
    Tanaka K, Norikane T, Mitamura K, Yamamoto Y, Maeda Y, Fujimoto K, Takami Y, Ishimura M, Arai-Okuda H, Tohi Y, Kudomi N, Sugimoto M, Nishiyama Y.
    EJNMMI Phys; 2022 Dec 05; 9(1):83. PubMed ID: 36469149
    [Abstract] [Full Text] [Related]

  • 7. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep 05; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 8. Accurate characterization of 99mTc-MDP uptake in extraosseous neoplasm mimicking bone metastasis on whole-body bone scan: contribution of SPECT/CT.
    Zhang L, He Q, Zhou T, Zhang B, Li W, Peng H, Zhong X, Ma L, Zhang R.
    BMC Med Imaging; 2019 May 30; 19(1):44. PubMed ID: 31146746
    [Abstract] [Full Text] [Related]

  • 9. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
    Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC.
    Lancet Oncol; 2022 Dec 30; 23(12):1499-1507. PubMed ID: 36343655
    [Abstract] [Full Text] [Related]

  • 10. Quantification evaluation of 99mTc-MDP concentration in the lumbar spine with SPECT/CT: compare with bone mineral density.
    Huang K, Feng Y, Liu D, Liang W, Li L.
    Ann Nucl Med; 2020 Feb 30; 34(2):136-143. PubMed ID: 31768820
    [Abstract] [Full Text] [Related]

  • 11. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases.
    Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod Lalonde M.
    BMC Musculoskelet Disord; 2019 Dec 26; 20(1):619. PubMed ID: 31878904
    [Abstract] [Full Text] [Related]

  • 12. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP.
    Pietrzak A, Czepczynski R, Wierzchoslawska E, Cholewinski W.
    Hell J Nucl Med; 2017 Dec 26; 20(3):237-240. PubMed ID: 29177262
    [Abstract] [Full Text] [Related]

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Dec 26; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 14. Maximum standardized uptake value from quantitative bone single-photon emission computed tomography/computed tomography in differentiating metastatic and degenerative joint disease of the spine in prostate cancer patients.
    Mohd Rohani MF, Mat Nawi N, Shamim SE, Wan Sohaimi WF, Wan Zainon WMN, Musarudin M, Said MA, Hashim H.
    Ann Nucl Med; 2020 Jan 26; 34(1):39-48. PubMed ID: 31612417
    [Abstract] [Full Text] [Related]

  • 15. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR.
    Eur Radiol; 2018 Feb 26; 28(2):610-619. PubMed ID: 28779400
    [Abstract] [Full Text] [Related]

  • 16. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I.
    J Nucl Med; 2006 Feb 26; 47(2):287-97. PubMed ID: 16455635
    [Abstract] [Full Text] [Related]

  • 17. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (99mTc-HMDP) Bone Scintigraphy for Bone Metastases from Prostate Cancer Using Deep Learning Algorithms.
    Higashiyama S, Yoshida A, Kawabe J.
    Curr Med Imaging; 2021 Feb 26; 17(1):89-96. PubMed ID: 32484112
    [Abstract] [Full Text] [Related]

  • 18. Prospective study of Na[18F]F PET/CT for cancer staging in morbidly obese patients compared with [99mTc]Tc-MDP whole-body planar, SPECT and SPECT/CT.
    Usmani S, Ahmed N, Gnanasegaran G, Al Kandari F, Marafi F, Bani-Mustafa A, Musbah A, Jassem Almashmoum M, Van den Wyngaert T.
    Acta Oncol; 2022 Oct 26; 61(10):1230-1239. PubMed ID: 35862646
    [Abstract] [Full Text] [Related]

  • 19. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
    Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD.
    J Nucl Med; 2012 Nov 26; 53(11):1670-5. PubMed ID: 22984218
    [Abstract] [Full Text] [Related]

  • 20. Differential diagnostic value of single-photon emission computed tomography/spiral computed tomography with Tc-99m-methylene diphosphonate in patients with spinal lesions.
    Zhang Y, Shi H, Gu Y, Xiu Y, Li B, Zhu W, Chen S, Yu H.
    Nucl Med Commun; 2011 Dec 26; 32(12):1194-200. PubMed ID: 21934544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.